Lukas Schüpbach has been a member of the board of Basel Area Business & Innovation since 2023.

He was previously CEO of Bacthera, a joint venture between Lonza & Chr Hansen, and cofounder of Innojection. Lukas has also held senior leadership positions at a Roivant Sciences portfolio company, Syngenta, and Novartis. He started his career as a Principal in Management Consulting at PwC.

Lukas Schüpbach holds a master’s degree in Business & General Management from the University of Basel and a master’s degree in Economics from HEC Lausanne. He is also an alumnus of several executive management programs at IMD and Harvard Business School.